Showing results (11-20 of 52) with videos related to
Sort By:
Pageof 6
Diabetes & Metabolic Syndrome|May 19, 2020
Thyroid dysfunction and its association with microvascular complications in patients with type 2 diabetes mellitus in south IndiaNishitha Reddy, T V S Pradeep, Sunanda Tirupati, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma modelFrancisco J Hernandez-Ilizaliturri, Nishitha Reddy, Beata Holkova, et al.Leukemia & Lymphoma|January 21, 2012
Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapyScott F Huntington, Mahsa S Talbott, John P Greer, et al.Clinical Lymphoma, Myeloma & Leukemia|June 15, 2013
Phase I trial of the HSP90 inhibitor PF-04929113 (SNX5422) in adult patients with recurrent, refractory hematologic malignanciesNishitha Reddy, Peter M Voorhees, Brett E Houk, et al.Clinical Lymphoma, Myeloma & Leukemia|September 18, 2012
Superior long-term outcome of patients with early transformation of non-Hodgkin lymphoma undergoing stem cell transplantationNishitha Reddy, Olalekan Oluwole, John P Greer, et al.Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|March 19, 2019
Age-dependent overall survival benefit of androgen deprivation therapy for metastatic prostate cancerMatthew J Keating, Lisa Giscombe, Toufic Tannous, et al.British Journal of Haematology|November 13, 2007
Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivoNishitha Reddy, Francisco J Hernandez-Ilizaliturri, George Deeb, et al.Experimental Hematology|January 25, 2012
Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignanciesWichai Chinratanalab, Nishitha Reddy, John P Greer, et al.Experimental Hematology|January 25, 2012
Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimenNishitha Reddy, John P Greer, Stacey Goodman, et al.The Lancet. Oncology|July 14, 2022
Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trialJohn M Pagel, Jacob D Soumerai, Nishitha Reddy, et al.Pageof 6